Brady 2004.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, parallel arm, fixed dose, double‐blind, 4 day tapering of medication at end of trial, single blind 1 week placebo run‐in BLINDING Participants: unclear Assessors: unclear Administrators: unclear ALLOCATION CONCEALMENT Method: unclear RANDOMISATION Method: urn randomisation by gender, depressive disorder, trauma type, and age of index trauma
Participants	SAMPLE Description: 94 DSM‐IV PTSD with concurrent alcoholism (LOCF sample), no war veterans, mean age: 36.7 years, 54% male, SCREENING Primary diagnosis: CAPS, SCID, CAPS >= 30% decrease after placebo run‐in grounds for exclusion Comorbidity: TLFB
Interventions	Description: sertraline (50 mg/d ‐ 150 mg/d) versus placebo (50 mg/d ‐ 150 mg/d) x 12 weeks
Outcomes	Outcomes: OCDS, CAPS, HAM‐D, SID, IES (not clear whether primary or secondary) Data estimation: LOCF (1 post‐baseline assessment)
Notes	INDUSTRY SUPPORT Industry funded: unclear Medication provided by industry: Yes Any of the authors work for industry: No ADDITIONAL INFORMATION Drop‐out rates: information not provided, 3 patients excluded as responders during placebo run‐in Quality rating score: 22
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear